DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status

Objective: Epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) is a first-line treatment for lung adenocarcinoma with EGFR-sensitive mutations, but acquired resistance to EGFR-TKIs remains a problem in clinical practice. The development of epithelial–mesenchymal transition (EMT) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Rui, Huang, Xuying, Liu, Heshu, Xiao, Zeru, Liu, Jian, An, Guangyu, Ge, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216632/
https://www.ncbi.nlm.nih.gov/pubmed/37239162
http://dx.doi.org/10.3390/biomedicines11051490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216632/
https://www.ncbi.nlm.nih.gov/pubmed/37239162
http://dx.doi.org/10.3390/biomedicines11051490

Ejemplares similares